Syncope in Patients with Autonomic Nervous System Disturbances:Which Diagnosis and Treatment?

Total Page:16

File Type:pdf, Size:1020Kb

Syncope in Patients with Autonomic Nervous System Disturbances:Which Diagnosis and Treatment? Syncope in Patients with Autonomic Nervous System Disturbances:Which Diagnosis and Treatment? C.J. MATHIAS Introduction Syncope is a condition in which there is transient loss of consciousness due to reduction in cerebral blood flow. The term syncope is often used synony- mously with fainting, blackouts, passing out, and swooning. It is a common condition with both neurological (autonomic and non-autonomic) and car- diac causes. Psychologic and psychiatric conditions resulting in pseudosyn- cope are difficult to separate from true syncope [1]. There is increasing recognition that disturbances of the autonomic ner- vous system account for a large proportion of syncope cases. This was emphasised in a study of 641 patients with recurrent syncope and presyn- cope, in whom major neurological (non-autonomic) and cardiac causes had been previously excluded [2]. Following autonomic and allied investigations, half of the patients had an autonomic cause (Fig. 1). This highlighted the role that the autonomic nervous system plays–in part through the baroreceptor reflex, with efferents to the heart and sympathetic efferents to blood vessels in the heart – in the maintenance of blood pressure and thus in the causation of syncope. This review provides a classification of disturbances of the autonomic nervous system that result in syncope. An outline of treatment options fol- lows. Neurovascular Medicine Unit, Faculty of Medicine; Imperial College London at St Mary’s Hospital, Autonomic Unit, National Hospital for Neurology & Neurosurgery, Queen Square; Institute of Neurology, University College London, London, United Kingdom 644 C.J.Mathias Fig. 1. Flow diagram showing investigations and diagnosis in 641 patients with recurrent syncope and presyncope. (Adapted from [2]) Diagnosis and Evaluation Autonomic disturbances resulting in syncope may be intermittent (neurally mediated syncope and the postural tachycardia syndrome) (Table 1), due to drugs (Table 2), or the result of damage to the autonomic nervous system as a result of primary or secondary autonomic failure [3, 4] (Table 3). Diagnosis is dependent on a precise history, detailed clinical examination, and appro- priate tests [5, 6] (Table 4). Table 1. Intermittent disturbances of the autonomic nervous system that cause syncope Neurally mediated syncope Vasovagal syncope Carotid sinus hypersensitivity Miscellaneous causes (situational syncope) Postural tachycardia syndrome (PoTS) Syncope in Patients with Autonomic Nervous System Disturbances:Which Diagnosis and Treatment? 645 Table 2. Mechanisms by which drugs, chemicals, poisons, and toxins may cause syncope. (adapted from [3]) By decreasing sympathetic activity Centrally acting Clonidine, reserpine, anaesthetics Peripherally acting via Sympathetic nerve endings (guanethidine, bethanidine) α-Adrenoceptor blockade (phenoxybenzamine) β-Adrenoceptor blockade (propranolol) By increasing cardiac parasympathetic activity Organophosphates Ciguatera (reef fish) poisoning By vasodilatation Jellyfish and marine animal venoms By a first-dose effect Prazosin, Captopril By causing an autonomic neuropathy Alcohol, thiamine (vitamin B1) deficiency Vincristine, perhexiline maleate Table 3. Disorders of the autonomic nervous system that cause syncope (adapted from [4]). Primary autonomic failure Acute/subacute dysautonomias Pure pandysautonomia Pandysautonomia with neurological features Chronic autonomic failure syndromes Pure autonomic failure Multiple system atrophy (Shy-Drager syndrome) Autonomic failure with Parkinson’s disease Secondary autonomic failure Congenital Nerve growth factor deficiency Hereditary Autosomal dominant trait Familial amyloid neuropathy continue ➝ 646 C.J.Mathias Table 3. continue Autosomal recessive trait Familial dysautonomia, Riley-Day syndrome Dopamine beta-hydroxylase deficiency Metabolic Diabetes mellitus Chronic renal failure Chronic liver disease Alcohol-induced Inflammatory Guillain-Barre syndrome Transverse myelitis Infections Bacterial: Tetanus Viral: Human immunodeficiency virus infection Neoplasia Brain tumours, especially of the third ventricle or posterior fossa Paraneoplastic, including adenocarcinomas of lung and pancreas Trauma Cervical and high thoracic spinal-cord transection Table 4. Outline of investigations used in the evaluation of syncope due to disturbances of the autonomic nervous system (adapted from [6]) Head-up tilt (60°)a; standinga; Valsalva manoeuvrea Pressor stimulia (isometric exercise, cold pressor, mental arithmetic) Heart rate responses to: deep breathinga, hyperventilationa, standinga, head-up tilta Liquid meal challenge Modified exercise testing Carotid sinus massage aIndicates screening autonomic tests used in our London Units Additional autonomic and allied tests, as described in [6], may need to be performed if relevant to diagnosis and management Syncope in Patients with Autonomic Nervous System Disturbances:Which Diagnosis and Treatment? 647 Treatment of Syncope Caused by Autonomic Nervous System Disturbances The key components of treatment revolve around non-pharmacological mea- sures, drug treatment when appropriate, and the introduction of interven- tions such as cardiac pacemaker when relevant. Neurally Mediated Syncope This depends upon the cause, the most common being vasovagal syncope (Fig. 2). Reducing or preventing exposure to precipitating causes is of impor- tance, along with educating the patient about the disorder. A combination of non-pharmacological approaches, especially if supine blood pressure is low, should include a high-salt diet; fluid repletion; exercise to strengthen lower limb muscles; measures that activate the sympathetic nervous system, such as sustained hand grip, the use of the calf muscle pump to prevent pooling; and various manoeuvres such as leg crossing [8–11]. Patients who have symptoms suggestive of an oncoming attack should sit and ideally lie head down, if needed with the legs upright. Pharmacological measures are used when non-pharmacological measures alone are not successful, especially if the supine blood pressure is low. These include low-dose fludrocortisone and Fig. 2. Blood pressure and heart rate with continuous recordings from the Portapres II in a patient with the mixed (cardio-inhibitory and vasodepressor) form of vasovagal syn- cope. (Adapted from [7]) 648 C.J.Mathias the sympathomimetics ephedrine and midodrine. 5-Hydroxytryptamine uptake release inhibitors have been used with varying success. In the cardio- inhibitory form of vasovagal syncope, a cardiac demand pacemaker is of value [12]. In some patients, especially those with phobias, cognitive behav- ioural psychotherapy is recommended. In carotid sinus hypersensitivity, which is diagnosed more often in older patients, a cardiac pacemaker often is of benefit, both in the cardio-inhibito- ry and in the mixed forms (Fig. 3). In the vasodepressor form, non-pharma- cological and drug treatment as outlined above for vasovagal syncope often is needed. In unilateral hypersensitivity, denervation of the carotid sinus nerves has been employed. In the miscellaneous (situational) group of syncope cases, treatment is tailored to the provoking cause. Thus, in patients with high spinal cord lesions on an artificial respirator, vagal activity is not opposed by sympathet- ic activity and tracheal stimulation can cause bradycardia and syncope; ade- quate oxygenation, atropine and, in some patients, a temporary cardiac demand pacemaker is indicated [14, 15]. In micturition-induced syncope, avoidance of precipitating factors, such as alcohol, and advice to empty the urinary bladder while sitting rather than standing may be all that is required. Fig. 3. Continuous blood pressure and heart rate measured non-invasively (by Portapres II) in a subject with falls of unknown cause. Left carotid sinus massage caused a fall in both heart rate and blood pressure. The findings indicate the mixed (cardioinhibitory and vasodepressor) form of carotid sinus hypersensitivity. (Adapted from [13]) Syncope in Patients with Autonomic Nervous System Disturbances:Which Diagnosis and Treatment? 649 Postural Tachycardia Syndrome In this condition (Fig. 4), non-pharmacological measures are of particular importance and include avoiding hypovolaemia and contributory factors such as hyperventilation. Drugs such as fludrocortisone and midodrine are of value in some patients. Beta-adrenergic blockers, especially those that are cardioselective, reduce tachycardia. Specific approaches may be needed depending upon the cause and association; thus, in the joint hypermobility syndrome, the underlying collagen disorder (Ehlers-Danlos type III) needs to be addressed. Drug-Induced Syncope The pharmacological effect of drugs, their interactions with other agents, and modification of their actions in certain disease states, need to be borne in mind when syncope results from drugs. The ideal is withdrawal of drugs, but this may not always be possible, as in the treatment of parkinsonian syn- dromes (Table 5). Drugs such as alcohol and perhexiline maleate cause an autonomic neuropathy, and withdrawal alone may not result in recovery. Fig. 4. Blood pressure and heart rate measured continuously before, during, and after 60° head-up tilt by Portapres II in a normal subject (uppermost panel) and in a subject with postural tachycardia syndrome (PoTS) (lowermost panel). (Adapted from [16]). The middle panel is from a subject with orthostatic hypotension due to autonomic failure 650 C.J.Mathias Table 5. The causative or contributory causes
Recommended publications
  • WHO Drug Information Vol. 12, No. 3, 1998
    WHO DRUG INFORMATION VOLUME 12 NUMBER 3 • 1998 RECOMMENDED INN LIST 40 INTERNATIONAL NONPROPRIETARY NAMES FOR PHARMACEUTICAL SUBSTANCES WORLD HEALTH ORGANIZATION • GENEVA Volume 12, Number 3, 1998 World Health Organization, Geneva WHO Drug Information Contents Seratrodast and hepatic dysfunction 146 Meloxicam safety similar to other NSAIDs 147 Proxibarbal withdrawn from the market 147 General Policy Issues Cholestin an unapproved drug 147 Vigabatrin and visual defects 147 Starting materials for pharmaceutical products: safety concerns 129 Glycerol contaminated with diethylene glycol 129 ATC/DDD Classification (final) 148 Pharmaceutical excipients: certificates of analysis and vendor qualification 130 ATC/DDD Classification Quality assurance and supply of starting (temporary) 150 materials 132 Implementation of vendor certification 134 Control and safe trade in starting materials Essential Drugs for pharmaceuticals: recommendations 134 WHO Model Formulary: Immunosuppressives, antineoplastics and drugs used in palliative care Reports on Individual Drugs Immunosuppresive drugs 153 Tamoxifen in the prevention and treatment Azathioprine 153 of breast cancer 136 Ciclosporin 154 Selective serotonin re-uptake inhibitors and Cytotoxic drugs 154 withdrawal reactions 136 Asparaginase 157 Triclabendazole and fascioliasis 138 Bleomycin 157 Calcium folinate 157 Chlormethine 158 Current Topics Cisplatin 158 Reverse transcriptase activity in vaccines 140 Cyclophosphamide 158 Consumer protection and herbal remedies 141 Cytarabine 159 Indiscriminate antibiotic
    [Show full text]
  • University of Groningen Clinical Studies with New Dopamine
    University of Groningen Clinical studies with new dopamine agonists Girbes, Armand Roelof Johan IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below. Document Version Publisher's PDF, also known as Version of record Publication date: 1991 Link to publication in University of Groningen/UMCG research database Citation for published version (APA): Girbes, A. R. J. (1991). Clinical studies with new dopamine agonists. s.n. Copyright Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons). The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license. More information can be found on the University of Groningen website: https://www.rug.nl/library/open-access/self-archiving-pure/taverne- amendment. Take-down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum. Download date: 02-10-2021 SUMMARY Dopamine, a naturally occurring catecholamine is extensively used in the intensive care setting. Dopamine exerts a complicated influence on the cardiovascularand renal system.This is due to the fact that dopamine stimulates different types of adrenergic receptors: not only o- and B-adrenergic but also specific dopamine receptors.
    [Show full text]
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report
    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
    [Show full text]
  • Transdermal Drug Delivery Device Including An
    (19) TZZ_ZZ¥¥_T (11) EP 1 807 033 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61F 13/02 (2006.01) A61L 15/16 (2006.01) 20.07.2016 Bulletin 2016/29 (86) International application number: (21) Application number: 05815555.7 PCT/US2005/035806 (22) Date of filing: 07.10.2005 (87) International publication number: WO 2006/044206 (27.04.2006 Gazette 2006/17) (54) TRANSDERMAL DRUG DELIVERY DEVICE INCLUDING AN OCCLUSIVE BACKING VORRICHTUNG ZUR TRANSDERMALEN VERABREICHUNG VON ARZNEIMITTELN EINSCHLIESSLICH EINER VERSTOPFUNGSSICHERUNG DISPOSITIF D’ADMINISTRATION TRANSDERMIQUE DE MEDICAMENTS AVEC COUCHE SUPPORT OCCLUSIVE (84) Designated Contracting States: • MANTELLE, Juan AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Miami, FL 33186 (US) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • NGUYEN, Viet SK TR Miami, FL 33176 (US) (30) Priority: 08.10.2004 US 616861 P (74) Representative: Awapatent AB P.O. Box 5117 (43) Date of publication of application: 200 71 Malmö (SE) 18.07.2007 Bulletin 2007/29 (56) References cited: (73) Proprietor: NOVEN PHARMACEUTICALS, INC. WO-A-02/36103 WO-A-97/23205 Miami, FL 33186 (US) WO-A-2005/046600 WO-A-2006/028863 US-A- 4 994 278 US-A- 4 994 278 (72) Inventors: US-A- 5 246 705 US-A- 5 474 783 • KANIOS, David US-A- 5 474 783 US-A1- 2001 051 180 Miami, FL 33196 (US) US-A1- 2002 128 345 US-A1- 2006 034 905 Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations.
    [Show full text]
  • Association of Oral Anticoagulants and Proton Pump Inhibitor Cotherapy with Hospitalization for Upper Gastrointestinal Tract Bleeding
    Supplementary Online Content Ray WA, Chung CP, Murray KT, et al. Association of oral anticoagulants and proton pump inhibitor cotherapy with hospitalization for upper gastrointestinal tract bleeding. JAMA. doi:10.1001/jama.2018.17242 eAppendix. PPI Co-therapy and Anticoagulant-Related UGI Bleeds This supplementary material has been provided by the authors to give readers additional information about their work. Downloaded From: https://jamanetwork.com/ on 10/02/2021 Appendix: PPI Co-therapy and Anticoagulant-Related UGI Bleeds Table 1A Exclusions: end-stage renal disease Diagnosis or procedure code for dialysis or end-stage renal disease outside of the hospital 28521 – anemia in ckd 5855 – Stage V , ckd 5856 – end stage renal disease V451 – Renal dialysis status V560 – Extracorporeal dialysis V561 – fitting & adjustment of extracorporeal dialysis catheter 99673 – complications due to renal dialysis CPT-4 Procedure Codes 36825 arteriovenous fistula autogenous gr 36830 creation of arteriovenous fistula; 36831 thrombectomy, arteriovenous fistula without revision, autogenous or 36832 revision of an arteriovenous fistula, with or without thrombectomy, 36833 revision, arteriovenous fistula; with thrombectomy, autogenous or nonaut 36834 plastic repair of arteriovenous aneurysm (separate procedure) 36835 insertion of thomas shunt 36838 distal revascularization & interval ligation, upper extremity 36840 insertion mandril 36845 anastomosis mandril 36860 cannula declotting; 36861 cannula declotting; 36870 thrombectomy, percutaneous, arteriovenous
    [Show full text]
  • Table of Contents (PDF)
    1 , I..,U i + i !, , i HearBritish Br Heart J: first published as on 1 July 1985. Downloaded from monthly journal of cardiology blished in association with eBritish Cardiac Society Journal m Editorial: strategies for preventing and screening 1 Functionless retained pacing leads in the for coronary heart disease MF Oliver cardiovascular system: a complication of Myocardial infarction and thrombolysis: pacemaker treatment FZerbe, A Ponizynski, electrocardiographic short term and long term WDyszkiewicz, A Ziemiahski, TDzi~gielewski, results using precordial mapping R von Essen, HKrug 76 WSchmidt, R Uebis, B Edelmann, S Effert, J Silny, G Rau 6 Effect of exercise on ventricular response to atrial Rupture of the myocardium: occurrence and risk fibrillation in Wolff-Parkinson-White factors MDellborg, P Held, KSwedberg, A Vedin 1 syndrome JCPCrick, D WDavies, PHolt, P V L Curry, ESowton 80 Effect of xamoterol (ICI 1 1 8587), a new beta, adrenoceptor partial agonist, on resting Intravenous sotalol for the treatment of atrial http://heart.bmj.com/ haemodynamic variables and exercise tolerance in fibrillation and flutter after cardiopulmonary patients with left ventricular dysfunction bypass: comparison with disopyramide and A O Molajo, D HBennett 17 digoxin in a randomised trial TJCampbell, How important is a history of chest pain in TP Gavaghan, JJ Morgan 86 determining the degree of ischaemia in patients Factors relating to the development of with angina pectoris? A A Quyyumi, CM Wright, hypertension after cardiopulmonary bypass L J Mockus, K M Fox 22 TTJ Cooper, TH Clutton-Brock, SNJones, J Tinker, Ischaemic heart disease and prodromes of sudden T Treasure 91 cardiac death: is it possible to identify high risk on October 2, 2021 by guest.
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Desensitization and Selective Down-Regulation of Rat Cardiac '31-Adrenoceptors by Prolonged in Vivo Infusion of T-0509, a 81-Adrenoceptor Full Agonist
    Desensitization and Selective Down-Regulation of Rat Cardiac '31-Adrenoceptors by Prolonged In Vivo Infusion of T-0509, a 81-Adrenoceptor Full Agonist Yoji Sato', Satomi Adachi-Akahane', Pablo Prados2, Kazuhiro Imai2 and Taku Nagao'°* 'Departmentof Toxicologyand Pharmacologyand 2Departmentof AnalyticalChemistry , Facultyof PharmaceuticalSciences, Universityof Tokyo,Hongo, Bunkyo-ku,Tokyo 113, Japan ReceivedJune 13, 1995 AcceptedSeptember 18, 1995 ABSTRACT-We studied the effects of prolonged infusion of a selective ~1-adrenoceptor (f3,AR) full agonist, T-0509 [(-)-(R)-1-(3,4-dihydroxyphenyl)-2-[(3,4-dimethoxyphenethyl)amino]ethanol hydrochlo- ride], with regard to its inotropic effect in vivo and cardiac (3AR density. The results were compared with those for isoproterenol. Continuous infusion of isoproterenol at doses of 2.5-40 ,ug/kg/hr, s.c. for 6 days shifted the dose-response curves of isoproterenol (i.v.) for LVdP/dtmx to the right and increased the ED50 values up to fourfold. Isoproterenol infusion at 40 pg/kg/hr reduced the density of both r3,- and ~2ARs by 36010and 43070 respectively, in left ventricular membranes. Following 6-day infusion of T-0509 at doses sufficient to induce a positive inotropic effect (5-40 rig/kg/hr), the ED50 value of T-0509 (i.v.) for LVdP/dtmax was also increased up to fourfold. In contrast to isoproterenol, infusion of T-0509 caused selective down-regulation of (3,ARs by 30% without changing the number of hARs. These results indicate that long-term application of a selective /31AR full agonist causes desensitization to its inotropy in vivo, with subtype-selective down-regulation of ~1ARs in cardiac ventricles.
    [Show full text]
  • The Effects of Dobutamine on Cardiac Sympathetic Activity in Patients with Congestive Heart Failure Abdul Al-Hesayen, MD, Eduardo R
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Journal of the American College of Cardiology Vol. 39, No. 8, 2002 © 2002 by the American College of Cardiology Foundation ISSN 0735-1097/02/$22.00 Published by Elsevier Science Inc. PII S0735-1097(02)01783-7 The Effects of Dobutamine on Cardiac Sympathetic Activity in Patients With Congestive Heart Failure Abdul Al-Hesayen, MD, Eduardo R. Azevedo, MD, Gary E. Newton, MD, John D. Parker, MD, FACC Toronto, Canada OBJECTIVES The goal of this work was to study the effects of short-term infusion of dobutamine on efferent cardiac sympathetic activity. BACKGROUND Increased efferent cardiac sympathetic activity is associated with poor outcomes in the setting of congestive heart failure (CHF). Dobutamine is commonly used in the therapy of decompensated CHF. Dobutamine, through its effects on excitatory beta-receptors, may increase cardiac sympathetic activity. METHODS Seven patients with normal left ventricular (LV) function and 13 patients with CHF were studied. A radiotracer technique was used to measure cardiac norepinephrine spillover (CANESP) before and during an intravenous infusion of dobutamine titrated to increase the rate of rise in LV peak positive pressure (ϩdP/dt) by 40%. RESULTS Systemic arterial pulse pressure increased significantly in response to dobutamine in the normal LV function group (74 Ϯ 3mmHgto85Ϯ 3 mm Hg, p ϭ 0.005) but remained unchanged in the CHF group. Dobutamine caused a significant decrease in LV end-diastolic pressure in the CHF group (14 Ϯ 2mmHgto11Ϯ 2 mm Hg, p ϭ 0.02), an effect not observed in the normal LV group.
    [Show full text]
  • Association of Oral Anticoagulants and Proton Pump Inhibitor Cotherapy with Hospitalization for Upper Gastrointestinal Tract Bleeding
    Supplementary Online Content Ray WA, Chung CP, Murray KT, et al. Association of oral anticoagulants and proton pump inhibitor cotherapy with hospitalization for upper gastrointestinal tract bleeding. JAMA. doi:10.1001/jama.2018.17242 eAppendix. PPI Co-therapy and Anticoagulant-Related UGI Bleeds This supplementary material has been provided by the authors to give readers additional information about their work. Downloaded From: https://edhub.ama-assn.org/ on 09/24/2021 Appendix: PPI Co-therapy and Anticoagulant-Related UGI Bleeds Table 1A Exclusions: end-stage renal disease Diagnosis or procedure code for dialysis or end-stage renal disease outside of the hospital 28521 – anemia in ckd 5855 – Stage V , ckd 5856 – end stage renal disease V451 – Renal dialysis status V560 – Extracorporeal dialysis V561 – fitting & adjustment of extracorporeal dialysis catheter 99673 – complications due to renal dialysis CPT-4 Procedure Codes 36825 arteriovenous fistula autogenous gr 36830 creation of arteriovenous fistula; 36831 thrombectomy, arteriovenous fistula without revision, autogenous or 36832 revision of an arteriovenous fistula, with or without thrombectomy, 36833 revision, arteriovenous fistula; with thrombectomy, autogenous or nonaut 36834 plastic repair of arteriovenous aneurysm (separate procedure) 36835 insertion of thomas shunt 36838 distal revascularization & interval ligation, upper extremity 36840 insertion mandril 36845 anastomosis mandril 36860 cannula declotting; 36861 cannula declotting; 36870 thrombectomy, percutaneous, arteriovenous
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Cannabinoid CB1 and CB2 Receptors Antagonists AM251 and AM630
    Pharmacological Reports 71 (2019) 82–89 Contents lists available at ScienceDirect Pharmacological Reports journal homepage: www.elsevier.com/locate/pharep Original article Cannabinoid CB1 and CB2 receptors antagonists AM251 and AM630 differentially modulate the chronotropic and inotropic effects of isoprenaline in isolated rat atria Jolanta Weresa, Anna Pe˛dzinska-Betiuk, Rafał Kossakowski, Barbara Malinowska* Department of Experimental Physiology and Pathophysiology, Medical University of Bialystok, Białystok, Poland A R T I C L E I N F O A B S T R A C T Article history: Background: Drugs targeting CB1 and CB2 receptors have been suggested to possess therapeutic benefit in Received 28 May 2018 cardiovascular disorders associated with elevated sympathetic tone. Limited data suggest cannabinoid Received in revised form 31 July 2018 ligands interact with postsynaptic β-adrenoceptors. The aim of this study was to examine the effects of Accepted 14 September 2018 CB1 and CB2 antagonists, AM251 and AM630, respectively, at functional cardiac β-adrenoceptors. Available online 17 September 2018 Methods: Experiments were carried out in isolated spontaneously beating right atria and paced left atria where inotropic and chronotropic increases were induced by isoprenaline and selective agonists of β1 and Keywords: β -adrenergic receptors. β-Adrenoceptor 2 Results: We found four different effects of AM251 and AM630 on the cardiostimulatory action of Cannabinoid receptor m AM251 isoprenaline: (1) both CB receptor antagonists 1 M enhanced the isoprenaline-induced increase in atrial AM630 rate, and AM630 1 mM enhanced the inotropic effect of isoprenaline; (2) AM251 1 mM decreased the Atria efficacy of the inotropic effect of isoprenaline; (3) AM251 0.1 and 3 mM and AM630 3 mM reduced the isoprenaline-induced increases in atrial rate; (4) AM630 0.1 and 3 mM enhanced the inotropic effect of isoprenaline, which was not changed by the same concentrations of AM251.
    [Show full text]